Clinical Research Awards
To accelerate NF research, CTF launched the Clinical Research Award (CRA) program in 2007 to support early stage pilot clinical trials of candidate therapeutics or interventions for treatment of manifestations of NF1, NF2 and schwannomatosis. In addition, these awards support innovative clinical trial enabling studies.
It is hoped that applications for Clinical Research Awards will be broad-thinking, novel ideas. Examples of projects encouraged may include but are not limited to the following:
- Preclinical/clinical collaborative studies. Note that all studies must include a clinical element – preclinical-only studies are not eligible
- Pilot clinical trials (CTF leverages our relationship with industry or larger funding organizations to provide drug at no cost to successful applicants.)
- Clinical enabling studies such as biomarker and patient stratification that may better inform and help accelerate a clinical trial.
It is anticipated that CTF will fund up to three Clinical Research Awards of up to $150,000 (including overheads and indirect costs).
We MUST RECEIVE your completed LOI at firstname.lastname@example.org
by 5:00 p.m. ET
Aug. 4, 2014*
LOIs received after this date will NOT be reviewed.
Submission Process: click HERE to download the LOI.
*The LOI deadline was moved to Aug. 4th to accommodate our researchers.
2013 Funded Clinical Trial Awards
Good manufacturing practice of clinical grade advanced-therapy medicinal product in regenerative therapy for congenital pseudarthrosis of the tibia in 5 individuals with neurofibromatosis type 1, Dr. Eric Legius
The Impact of Ras/MAPK signaling pathway-targeted therapies on neurocognitive functioning in youth with NF1, Dr. Karin Walsh, Children's Research Institute
Resiliency training for patients with Neurofibromatosis via videoconferencing with Skype, Dr. Ana-Marie Vranceanu, Massachusetts General Hospital
2012 Funded Clinical Trial Awards
A Phase II Randomised Placebo-Controlled Double-Blind Cross-Over Trial of Methylphenidate in Children with Neurofibromatosis Type1, Dr. Kathryn North, The Children’s Hospital at Westmead
Effect of creating visual illness narratives on quality of life in children with Neurofibromatosis type 1: a pilot intervention study, Dr. Nicole Ullrich, Boston Children's Hospital
Effect of anti-VEGF and radiation on NF2 vestibular Schwannoma Schwannoma, Dr. Lei Xu, Massachusetts General Hospital
2011 Funded Clinical Trial Awards
Phase II Trial of Rapamycin - NF2 Tumors
Dr. Matthias Karajannis, New York University Langone Medical Center
New metrics for optic pathway glioma trials
Dr. Robert Avery, Children’s National Medical Center
Blood predictors of NF1 severity
Dr. Cynthia Hingtgen, Indiana University
Computerized ‘maze’ for NF1 learning disabilities trials
Dr. Nicole Ullrich, Children’s Hospital Boston
2014 CRA Application Window
August 4, 2014 - LOI due
August 18, 2014 - Invitation to full application
September 30, 2014 - Full application due
Notifications will be made in early November 2014